Cerus (CERS) 8-K Cerus Reports Initial Results from Additional Analysis of the U.s. Phase Iii Data for the Intercept Blood System for Platelets

Exhibit 99.2

Respiratory Adverse Events

Expert Panel Assessment vs. Bernard Criteria vs. Adverse Events (as coded)

I. Expert Panel Assessment	Event Frequency			Mortality Rates
	Test	Ref
	(N=318)	(N=327)	p-Value	Test	Ref	p-Value
Acute Lung Injury (ALI)	7 (2.2%)	11 (3.4%)	0.48	0/7 (0%)	6/11 (55%)	0.04
Acute Respiratory Distress	12 (3.8%)	5 (1.5%)	0.09	9/12 (75%)	5/5 (100%)	0.52
Syndrome (ARDS)
Combined ALI/ARDS	19 (6.0%)	16 (4.9%)	0.60	9/19 (47%)	11/16 (69%)	0.31

II. Bernard Criteria
Assessment*	Event Frequency
	Test	Ref
	(N=318)	(N=327)	p-Value
Acute Lung Injury (ALI)	8 (2.5%)	10 (3.1%)	0.81
Acute Respiratory Distress	11 (3.5%)	5 (1.5%)	0.13
Syndrome (ARDS)
Combined ALI/ARDS	19 (6.0%)	15 (4.6%)	0.48

III. Adverse Events (as coded)	Event Frequency
	Test	Ref
	(N=78)	(N=70)	p-Value
Combined ALI/ARDS	10† (12.8%)	1 (1.4%)	0.01

Excludes patients with ALI or ARDS at baseline

^† Includes 1 patient with ALI verbatim

*Bernard GR, Artigas A, Brigham, KL, et al.  The American-European Consensus Conference on ARDS.
Am J Respir Crit Care Med Vol 149 pp 818-824, 1994